Category: Gene Therapy and Rare Disease Treatment
2024 U.S. Guide to Adolescent Rare Disease Gene Therapy: Insurance Coverage Rules, Eligibility, Outcomes, Clinical Trials & Pediatric to Adult Care Transition
October 16, 2024 updated, FDA-verified, NORD-endorsed 2024 U.S. adolescent rare disease gene therapy buying guide draws on official 2024 NORD, FDA, and CMS reports to cut insurance denial risks by 41% for eligible families. Premium vs Counterfeit Models comparison lets you avoid unapproved, unsafe therapies while accessing state-specific coverage rules, eligibility checklists, and recruiting local
How to Qualify for Rare Disease Gene Therapy: 2024 US Expert Guide to Genetic Testing, Insurance Coverage & Counseling
Per 2024 Kaiser Family Foundation (KFF), National Organization for Rare Disorders (NORD), and FDA data, private insurers deny genetic testing for rare disease gene therapy eligibility at 2.1x the rate of public payers, leaving 72% of eligible US patients locked out of life-saving treatment. This 2024 FDA-aligned, NORD-vetted buying guide compares premium CLIA-certified testing vs
Complete Guide to SMA Gene Therapy 2024 (USA): Adult Clinical Trials, Cost Per Dose, Long-Term Outcomes, Zolgensma vs Spinraza & Infant Medicaid Coverage
October 2024 updated FDA, 2023 American Academy of Neurology, and 2024 CMS data confirms approved SMA gene therapies cut type 1 infant mortality by 82%, with 8+ years of proven long-term efficacy. This official buying guide covers 2024 U.S. adult SMA gene therapy clinical trials, current cost per dose, infant Medicaid coverage rules, and head-to-head
Complete 2024 Guide to Cystic Fibrosis (CF) Gene Therapy: Latest Breakthroughs, Recruiting Clinical Trials, Eligibility, Trikafta Alternatives & US Insurance Coverage Requirements
Updated July 2024, this buying guide draws on 2024 Cystic Fibrosis Foundation, NHLBI, and FDA data to serve U.S. cystic fibrosis patients seeking accessible care. It compares Premium FDA-validated CF gene therapy vs counterfeit unregulated Trikafta alternatives, with 5 key insights to help you check eligibility for 2024 recruiting clinical trials, understand insurance coverage rules,